Various oncolytic viruses carrying shRNA have been reported to effectively enhance therapeutic outcomes, for example, oncolytic adenoviruses encoding shRNA effectively downregulate target proteins such as DNA-PKcs, Apollon, and VEGF, enhancing radiation sensitivity, antitumor effects of 5-fluorouracil, and inhibiting angiogenesis and tumor growth in various cancer models [40–42]. The gene discussed is PRKDC; the disease is neoplasm.